Kyverna Therapeutics (KYTX) Accounts Payables (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Accounts Payables came in at $11.6 million in Q1 2026, up 36.96% YoY from $8.5 million in Q1 2025, and up 118.68% on a QoQ basis from $5.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) Accounts Payables (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Accounts Payables data on file, last reported at $11.6 million in Q1 2026.
- Quarterly Accounts Payables rose 36.96% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 36.96% YoY) and the FY2025 annual result came in at $5.3 million, up 14.75% from the prior year.
- Accounts Payables improved to $11.6 million in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $11.6 million in Q1 2026 to a low of $3.0 million in Q3 2025.
- A 4-year average of $7.0 million and a median of $6.4 million in 2024 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 104.01% in 2025, down 69.63% in 2025.
- Tracing KYTX's Accounts Payables over 4 years: stood at $4.4 million in 2023, then advanced by 6.1% to $4.6 million in 2024, then advanced by 14.75% to $5.3 million in 2025, then soared by 118.68% to $11.6 million in 2026.
- The last three Accounts Payables figures came in at $11.6 million (Q1 2026), $5.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 2.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.93 Mn |
| Mar 31, 2026 | 11.60 Mn |
| Dec 31, 2025 | 5.31 Mn |
| Sep 30, 2025 | 3.02 Mn |
| Jun 30, 2025 | 9.92 Mn |
| Mar 31, 2025 | 8.47 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 4.86 Mn |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 4.36 Mn |